An approved breast-cancer drug nab-paclitaxel, trade named Abraxane, has been found promising in clinical trial for the treatment of metastatic malignant melanoma, revealed by researchers.
Researchers at the Arizona Cancer Center has used this drug for last 7 years, and resulted in the opening of a Phase 3 clinical trial.
For more information: Breast cancer drug Abraxane promising for malignant melanoma treatment